A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of AF-130 in Healthy Subjects.

Trial Profile

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of AF-130 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs AF 130 (Primary)
  • Indications Hypertension; Migraine
  • Focus Adverse reactions
  • Sponsors Afferent Pharmaceuticals
  • Most Recent Events

    • 27 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jun 2016.
    • 18 May 2016 According to a Afferent Pharmaceuticals media release, status changed from recruiting to completed.
    • 11 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top